UBS Initiates Coverage on Addus Homecare with Buy Rating, PT $145
ByAinvest
Tuesday, Sep 2, 2025 8:18 am ET1min read
ADUS--
Addus Homecare Corporation is engaged in providing home care services, with its segments including Personal Care, Hospice, and Home Health. The Personal Care segment offers non-medical assistance with activities of daily living, while the Hospice segment provides physical, emotional, and spiritual care for terminally ill individuals. The Home Health segment provides medical services to individuals requiring assistance during illness or after hospitalization [2].
UBS's price target of $145 suggests a bullish outlook on the company's future prospects, although the firm maintains a neutral rating on the stock. The rating reflects the firm's assessment of Addus Homecare's strong performance in the home care market and its recent strategic initiatives.
Investors should closely monitor Addus Homecare's financial performance and analyst ratings to make informed decisions. Despite the increased investment and positive outlook, the stock remains volatile, with a 12-month low of $2.75 and a 12-month high of $4.50 [3].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_FWN3UJ10D:0-addus-homecare-corp-files-for-mixed-shelf-size-not-disclosed/
[2] https://www.marketscreener.com/news/addus-homecare-corp-files-for-mixed-shelf-size-not-disclosed-ce7c50ded08df225
[3] https://www.ainvest.com/news/ubs-raises-petco-health-pt-3-7-maintains-neutral-rating-2508/
UBS Initiates Coverage on Addus Homecare with Buy Rating, PT $145
UBS Group AG has initiated coverage on Addus Homecare Corporation (ADUS) with a buy rating and a price target of $145. The financial services firm's positive outlook comes as Addus Homecare Corp recently filed for a mixed shelf offering, with the size of the offering not disclosed [1].Addus Homecare Corporation is engaged in providing home care services, with its segments including Personal Care, Hospice, and Home Health. The Personal Care segment offers non-medical assistance with activities of daily living, while the Hospice segment provides physical, emotional, and spiritual care for terminally ill individuals. The Home Health segment provides medical services to individuals requiring assistance during illness or after hospitalization [2].
UBS's price target of $145 suggests a bullish outlook on the company's future prospects, although the firm maintains a neutral rating on the stock. The rating reflects the firm's assessment of Addus Homecare's strong performance in the home care market and its recent strategic initiatives.
Investors should closely monitor Addus Homecare's financial performance and analyst ratings to make informed decisions. Despite the increased investment and positive outlook, the stock remains volatile, with a 12-month low of $2.75 and a 12-month high of $4.50 [3].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_FWN3UJ10D:0-addus-homecare-corp-files-for-mixed-shelf-size-not-disclosed/
[2] https://www.marketscreener.com/news/addus-homecare-corp-files-for-mixed-shelf-size-not-disclosed-ce7c50ded08df225
[3] https://www.ainvest.com/news/ubs-raises-petco-health-pt-3-7-maintains-neutral-rating-2508/

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet